Migraine Headache Clinical Trial
Official title:
TENACITY: TelemEdiciNe-bAsed Cognitive Therapy for Migraine
The goal of this pilot study is to evaluate a bundle of implementation strategies at three Veteran Affairs Medical Centers (VAMCs) to facilitate the referral and adoption of a telehealth based, cognitive behavioral therapy program delivered by Health Psychologists for Veterans with chronic migraine to inform a future fully-powered hybrid type 2 effectiveness-implementation design. Veteran patients will be randomized to either the telehealth delivered CBT or usual care. Headache symptoms and severity will be reported using a VA text messaging application.
With VHA's infrastructure dedicated to efficient telehealth delivery into patient homes, the delivery of a behavioral intervention for chronic migraine, CM, via the telehealth platform is primed to address barriers of in-person care delivery and holds considerable promise to reach and improve Veteran headache-related quality of life. Therefore, the goal is to evaluate an adapted bundle of EB implementation strategies to increase adoption of a Telemedicine-based Cognitive Behavioral Therapy (CBT) program (TENACITY) for CM in 2 VA HCoEs (VA Connecticut Healthcare System [VACHS], a large, multi-disciplinary HCoE, and Birmingham VA Medical Center [BVAMC], a smaller VA Headache Consortium Center. The HCoEs are charged with improving headache care throughout the VA, not just within an individual VAMC. As part of this study, a non-HCoE will also participate, providing an opportunity for the TENACITY study to extend this virtual specialty headache care to Veterans without headache specialty care. Dallas VA Medical Center, also known as the North Texas Health Care System [NTHCS] will participate as a third site. The investigators will determine whether TENACITY can be efficiently delivered through the vehicle of telehealth by conducting a pilot randomly controlled trial (RCT) comparing a) TENACITY to b) behavioral treatment as usual (TAU; i.e., behavioral usual care). The investigators will recruit Veterans diagnosed with chronic migraine during the one-year recruitment period across the 3 VAMCs. The investigators will randomize eligible Veterans to participate either in the TENACITY intervention (n=50) or treatment as usual (n=50). The specific aims are threefold: Aim 1: To develop a bundle of evidence-based practice (EBP) implementation strategies to engage 3 VA Medical Centers [2 Headache Centers of Excellence HCoEs and 1 general neurology service] and facilitate their local adaptation and implementation of Cognitive Behavioral Therapy (CBT) (TENACITY) through the vehicle of telehealth services. Hypothesis 1a. HCoE clinical providers will report high acceptability, appropriateness and fidelity of TENACITY at 3 months and maintenance at 6 months. Hypothesis 1b. TENACITY reach, adoption, and implementation will vary by HCoE local context as evaluated by the Consolidated Framework for Implementation Research (CFIR) inner settings. Aim 2. To conduct a pilot RCT and determine the preliminary efficacy and feasibility of TENACITY compared to TAU across 3 VA sites. Hypothesis 2: Veterans receiving TENACITY will experience a statistically significant reduction in routine clinical headache metrics: headache frequency [headache days per month] (primary outcome), headache-related impairment and psychological symptoms (secondary outcomes) compared to usual care at 3 and 6 months. Aim 3: The investigators will conduct exploratory cost analysis of TENACITY from the Veteran's perspective, using inputs from the pilot RCT, and a two-year budget impact analysis from the VHA's perspective, incorporating the costs of implementation as well as direct costs (and cost-savings,) of providing the TENACITY intervention over all HCoEs to VHA. Hypothesis 3: TENACITY will be cost-effective and provide value to Veterans and VHA. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
Completed |
NCT01211145 -
Zomig - Treatment of Acute Migraine Headache in Adolescents
|
Phase 4 | |
Completed |
NCT00530517 -
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
|
Phase 2 | |
Completed |
NCT00898677 -
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
|
Phase 3 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT03971071 -
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
|
Phase 4 | |
Withdrawn |
NCT02706015 -
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
|
Phase 3 | |
Completed |
NCT02518464 -
Ticagrelor Therapy for RefrACTORy Migraine Study
|
Phase 4 | |
Terminated |
NCT02375789 -
Intranasal Cooling for Symptomatic Relief of Migraine
|
N/A | |
Terminated |
NCT00391755 -
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
|
Phase 4 | |
Completed |
NCT03401346 -
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
|
Phase 1 | |
Completed |
NCT05085483 -
Ketone for Migraine Prevention
|
N/A | |
Completed |
NCT01604785 -
Low-dose Propofol for Pediatric Migraine
|
Phase 2/Phase 3 | |
Terminated |
NCT00804973 -
Study in Participants With Acute Migraines Headaches
|
Phase 2 | |
Completed |
NCT03341689 -
Psilocybin for the Treatment of Migraine Headache
|
Phase 1 | |
Completed |
NCT01630044 -
Neurostimulation Device for Treatment of Migraine Headache
|
N/A | |
Active, not recruiting |
NCT00285402 -
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
|
Phase 2 | |
Completed |
NCT00203255 -
Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache
|
N/A | |
Recruiting |
NCT06046508 -
Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
|